Swedish Orphan Biovitrum AB (publ)
Health Care
Current price
Target price 00%
Ranks rating
76
Position in sub-industry
246 / 1361
Position in country
501 / 1532
Return on Assets, %
3.8
-40.3
Debt to Equity, %
60.4
3.2
Intangible assets and goodwill, %
81.2
0.2
Revenue CAGR 3Y, %
13.1
12.5
Total Equity change 1Y, %
32
-9
Revenue Y, % chg
14.6
0
P/E
34.7
31
P/BV
2.5
1.8
P/S
4
10.3
EV/S
4.9
7.5
EV/EBITDA
14.2
-1.6
Average Analyst recommendation
Buy
Buy
Average upside forecasts, %
119.3
131.1
Forward P/E
21
21.4
Expected dividend per share
0
0
Competitors
Ranks
-
Vertex Pharmaceuticals Inc
00%
-
CSL Ltd
00%
-
Regeneron Pharmaceuticals Inc
00%
-
Bonesupport Holding AB
00%
-
Swedish Orphan Biovitrum AB (publ)
00%
-
Biogaia AB
00%
-
Amgen Inc
00%
-
BioArctic AB
00%
-
AbbVie Inc
00%
-
Vitrolife AB
00%
Ready-made portfolio of the best Russian stocks
- Created by artificial intelligence
- Verified by analysts
- Available even to beginners
Company information
Country
Sweden
Sector
Health Care
Industry group
Pharmaceuticals, Biotechnology & Life Sciences
Industry
Biotechnology
Sub-sector
Health Care
Capitalization (millions of $)
8353.7
Ticker
SWOBY.PK
ISIN
US8703212055
IPO date
2006-09-15
Availability on Russian exchanges
No
Reporting for
Date fact. publication of reports
Company Description
Swedish Orphan Biovitrum publ AB is a Sweden-based pharmaceutical company. The Company develops, manufactures and sells medications within hemophilia, autoimmune diseases, metabolic diseases and cancer supportive care. The Company’s product portfolio is divided into three business segments: the Core Products segment offers pharmaceuticals within Inflammation area, and Genetics and metabolic therapeutic area; the Partner Products segment offers about 40 pharmaceuticals within hematology, oncology and emergency medicines, and the ReFacto Manufacturing segment. The Company has subsidiaries in Sweden, Denmark, Finland, Norway, United Kingdom and France, among others. On September 9, 2013, the Company acquired the full rights to develop and commercialize Kineret (anakinra) from Amgen, the biotechnology company based in the United States.
A step towards better analytics
- find the best promotions through the Screener
- keep an eye on stock valuation
- download detailed reports
and much more after free registration
RegistrationMore convenient from your phone? Download: